Zacks Research Weighs in on Clorox’s Q2 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Zacks Research decreased their Q2 2026 earnings estimates for shares of Clorox in a report issued on Monday, November 17th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.46 for the quarter, down from their previous estimate of $1.52. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q3 2026 earnings at $1.55 EPS, Q4 2026 earnings at $2.09 EPS, FY2026 earnings at $5.95 EPS, Q1 2027 earnings at $1.32 EPS, Q2 2027 earnings at $1.61 EPS, Q4 2027 earnings at $2.18 EPS, FY2027 earnings at $6.80 EPS, Q1 2028 earnings at $1.25 EPS and FY2028 earnings at $7.14 EPS.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same period last year, the firm posted $1.86 earnings per share. The business’s revenue was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS.

Other analysts have also issued research reports about the company. Barclays cut their price objective on Clorox from $112.00 to $108.00 and set an “underweight” rating for the company in a report on Tuesday, November 4th. Wells Fargo & Company dropped their price target on shares of Clorox from $125.00 to $117.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. BNP Paribas Exane reduced their price objective on shares of Clorox from $110.00 to $103.00 and set an “underperform” rating for the company in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Clorox in a report on Tuesday, October 14th. Finally, Rothschild & Co Redburn cut their target price on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $125.69.

Clorox Stock Performance

Shares of NYSE CLX opened at $100.10 on Tuesday. The stock has a fifty day moving average price of $116.67 and a two-hundred day moving average price of $122.95. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The firm has a market cap of $12.21 billion, a P/E ratio of 15.35, a PEG ratio of 0.92 and a beta of 0.52. Clorox has a 1 year low of $99.63 and a 1 year high of $171.37.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 5.0%. The ex-dividend date is Wednesday, January 28th. Clorox’s payout ratio is presently 77.86%.

Insider Transactions at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.63% of the stock is currently owned by company insiders.

Institutional Trading of Clorox

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. grew its holdings in shares of Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock valued at $389,648,000 after acquiring an additional 1,883,465 shares in the last quarter. Norges Bank purchased a new position in Clorox in the second quarter valued at about $190,429,000. Van ECK Associates Corp raised its stake in shares of Clorox by 93.9% during the 3rd quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock worth $334,139,000 after purchasing an additional 1,312,471 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Clorox by 218.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock valued at $149,983,000 after buying an additional 856,873 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Clorox in the 2nd quarter valued at approximately $71,856,000. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.